Archives
CP-673451 and the Next Era of PDGFR Research
2026-10-03
A translational perspective on CP-673451 as a selective PDGFRα/β inhibitor, connecting target engagement, angiogenesis biology, xenograft evidence, and ATRX-aware glioma research while distinguishing preclinical promise from clinical proof.
Tivozanib (AV-951) Assay Workflow Guide
2026-10-02
Build more informative VEGFR experiments with Tivozanib (AV-951), from compound preparation and pathway confirmation to paired viability and cell-death measurements. This workflow helps distinguish cytostatic effects from true killing and supports renal cell carcinoma, endothelial, and combination-treatment studies.
In Vitro Drug Response: Growth Inhibition vs Cell Death
2026-10-01
Hannah R. Schwartz’s 2022 dissertation distinguishes relative viability from fractional viability, showing that these commonly interchanged metrics capture different relationships between proliferative arrest and cell death. The framework provides a practical basis for designing time-resolved cancer assays and interpreting drug responses without treating reduced viability as a direct synonym for cytotoxicity.
In Vitro Drug Response Metrics in Cancer
2026-10-01
Schwartz’s dissertation, In Vitro Methods to Better Evaluate Drug Responses in Cancer, distinguishes relative viability from fractional viability when interpreting anticancer drug responses. Its central implication is that growth inhibition and cell killing should be measured and timed separately because they can occur in different proportions and with different kinetics.
Gingerenone A Restores Sunitinib Sensitivity in RCC
2026-09-30
The January 2026 reference study identifies gingerenone A as a metabolic intervention that inhibits LDHA-driven glycolysis and improves sunitinib activity in renal cell carcinoma models. Its combination of network pharmacology, target-interaction analysis, metabolic assays, rescue experiments, and in vivo validation links lactate metabolism to HIF-1α/VEGFA/VEGFR2 signaling and TKI resistance.
Nile Red Workflow for Lipid Droplet Research
2026-09-30
Use Nile Red as a two-channel fluorescent lipid probe to distinguish broad membrane-associated signal from lipid droplet-enriched signal. This workflow translates lipid metabolism findings in laryngeal cancer into practical imaging, quantification, and troubleshooting decisions without overstating what the reference study directly demonstrated.
Nintedanib Assay Design for ATRX-Aware Models
2026-09-29
Nintedanib and BIBF 1120 offer a practical way to interrogate coordinated VEGFR, FGFR, and PDGFR signaling. This article translates ATRX-deficient glioma findings into biomarker-aware assay design while clarifying evidence limits across cancer and fibrosis models.
PD 173074: FGFR1 and VEGFR2 Assay Workflows
2026-09-29
PD 173074 connects nanomolar FGFR1 pharmacology with measurable VEGFR2 inhibition for mechanistic studies of angiogenesis, tumor signaling, and treatment resistance. This workflow-focused guide covers assay setup, concentration selection, translational model design, and troubleshooting.
Viral vIRD Targets RIPK3 to Control Inflammation
2026-09-28
The reference study identifies a cowpox virus protein family that recruits host SCF ubiquitin-ligase machinery to degrade RIPK3, thereby suppressing necroptosis while paradoxically enhancing viral replication and inflammatory disease. Its combination of viral genetics, host-deficiency models, and biochemical analysis provides a framework for linking pathogen evolution with regulated cell death and in vivo pathogenesis.
Cabozantinib in RCC: A Practical Research Workflow
2026-09-28
Turn Cabozantinib’s multi-kinase activity into a reproducible RCC workflow that separates acute response from chronic adaptation. Practical guidance covers dose selection, phosphoproteomics, motility assays, and common formulation pitfalls.
CP-673451 in PDGFR Signaling and Glioma Research
2026-09-27
Use CP-673451 to test PDGFRα/β dependence across signaling, angiogenesis, and tumor-growth assays—with potency and selectivity data to guide assay design. A practical workflow also shows how to compare ATRX-deficient and ATRX-proficient glioma cells without assuming that findings from other inhibitors automatically apply to CP-673451.
Trolox C3183 for Reproducible Oxidative Stress Assays
2026-09-26
A practical guide to using Trolox (SKU C3183) as an antioxidant control in cell-based and chemical assays. It covers assay compatibility, stock preparation, interpretation, and evidence-based product selection without treating chemical radical scavenging as proof of cellular protection.
Separating Cancer Cell Growth Arrest from Cell Death
2026-09-25
Hannah R. Schwartz’s dissertation highlights that relative viability and fractional viability measure different parts of an anticancer response: changes in proliferation and cell killing. Its practical message is to distinguish these outcomes and follow their timing rather than relying on a single viability endpoint.
Pexidartinib (PLX3397) in Microglial Research
2026-09-25
Use Pexidartinib (PLX3397) to test whether CSF1R-dependent myeloid-cell activity contributes to microglial and synaptic changes—not to assume it reproduces minocycline’s effects. This workflow pairs dose finding and target-engagement checks with practical controls for translating a cancer-research inhibitor into a carefully bounded neurobiology experiment.
NU7441 (KU-57788) in Cell Assays
2026-09-24
Practical guidance for using NU7441 (KU-57788) to investigate DNA-PK-dependent DNA damage responses in viability, cytotoxicity, and cell-cycle experiments. This scenario-driven guide covers controls, formulation, interpretation, and selection considerations for SKU A8315.
605 records 6/41 page Previous Next First page 上5页 678910 下5页 Last page